CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...
Cabozantinib plus nivolumab showed a 71% response rate in FH-dRCC, extending efficacy beyond non-clear cell RCC. The study ...
The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...
Tovorafenib provides durable disease control in pediatric patients with relapsed or refractory low-grade glioma harboring ...
This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...
This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous ...
This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and ...
Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...
The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment with myelosuppressive anticancer drugs linked to a significant chance of ...
November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...
Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as demonstrated by the PRESTO, EMBARK, and ENZARAD trials. The PRESTO trial ...
Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback